. ,

.
,
.
«
»,
.
–
,
.
.
Helicobacter pylori
-
.
,
.
:
,
-
-17,
.
-
.
(
)
:
,
, Helicobacter pylori,
.
,
,
,
-
,
,
There are two tendencies in the conservative therapy of the gastroduodenal ulcers. The first one is
an anti-secretory therapy which permits to achieve ulcer reparation or to prevent ulcer formation while
taking antacid preparations. During the period of ulcer treatment a patient has to take inhibitor of the
protonic pump in the standard dosage. The second tendency in the treatment of gastroduodenal ulcers
implies eradication of Helicobacter pylori strictly according to the definite rules. In case of successful
eradication one may observe decrease in frequency of ulcer recurrence as well as of ulcerous bleedings
and perforations. Also positive changes of the functional and morphological characteristics of the stomach
mucous membrane are registered: the level of serumal gastrin-17 decreases, inflammatory and atrophic
changes in the stomach mucous membrane also reduce.
One more actual cause for ulcer forming is intake of aspirin and of non-steroid anti-inflammatory
preparations. In case of ulcer anamnesis or presence of risk factors a patient should receive the inhibitor of
the protonic pump in the standard dosage during the whole period of aspirin or non-steroid anti-inflammatory
preparations intake (days or years).
Keywords: gastric ulcer, duodenal ulcer, ulcerous bleeding, ulcer perforation, Helicobacter pylori,
eradication therapy, anti-secretory therapy, aspirin, non-steroid anti-inflammatory preparations
.
-
:
(
),
,
-
,
.
-
8 8
1 2009
17
-
-
.
.
.
3–7
-
.
–
(
).
-
4–6
– 6–8
Helicobacter pylori (H.pylori) ,
,–
.
,
,
.,
.
1–2
-
-
,
-
.
,
,
–
.
(
.
.
,
)
,
-
:
.
,
,
-
H.pylori.
.
,
.
.
,
.
–
,
( ,
-
)
.
1910 .
:«
–
».
.
,
–
(
,
,
,
-
–
.
H.pylori,
(
– 30
– 20
20 ,
– 40 ,
– 20 ),
.
.
,
,
–
,
,
30–60
-
,
.
.
-
)
-
-
.
H.pylori
89
:
(
2
2
.
500
1000
,
2
.
20–30
[1, 2].
,
.
-
-
–
500
.
)
+
+
2
.
-
,
.
,
147-
,
»
.
«
2005 .
7
.
»,
«
.
.
14
-
-III
12%.
.
-
55
,
.
.
–
-
.
:
,
–
.
1–2
,
-
.
2
120
+
+
–
4
,
20–30
2
20
+
-
20–30
500
4
500
3
.
-
,
.
,
,
-
,
,
,
– «compliance».
,
,
.
–
, 10- ,
9 0
14-
7-
1–2
,
1 2009
17
.
.
,
(
.
-III
.
(500
(
2
(1000
,
.
2
,
.
-
,
,
.
7
10
(PP – per
,
,
)
–
1–
-
,
– 63–86% [3].
H.pylori (
.
,
)
)
4%
,
)
)
)+
2
.
protocol,
-
-
,
:
,
(
),
,
.
–
-
.
H.pylori
.
.
.
,
,
-
-
,
-
.
.
.
:
,
.
-
,
-
,
,
-
«
».
,
,
,
-
.
(
)
(
,
,
)
2–3
.
-
,
2–3
-
«
»
.
91
.
,
,
,
-
,
,
.
,
-
.
,
,
.
2001 .
«
)
»
(
-II.
:
804,
,
– 444
10%
.
.
(
-
-
)
.
.
,
.
-
,
2006 .
(79,0%),
.
635
,
– 259
58,3%
.
.
2007 .
.
,
,
,
,
-
,
.
.
-
,
5
,
.
401
,
49,4%
,
, 9,7%
.
-
-
.
:
.
H.pylori,
.
,
,
,
-
,
41%
.
,
,
-
.
9 2
,
,
.
?
-
,
,
,
1 2009
17
.
J.P. Gisbert
.
,
H.pylori
:
,
-
2,9%,
20%,
(OR)
0,17 (95% CI: 0,10–0,32); NNT
-
(95% CI: 5–11) [3].
7
.
,
,
-
(
-
.
27%
-
)
-
:
1,6% 5,6%
(OR = 0,24; 95% CI: 0,10–0,32).
-
.
.
,
-
SF-36
,
H.pylori
-
,
[4].
.
:
)
.
,
,
,
-
1–3
–
[5].
-
2.
,
(
-
,
(
.
42,6%),
29,3%)
( 16,8
47,8%.
,
.
-
-
-I
).
-17,
-II [6].
-III
93
.
H.pylori
-
: «
.pylori
.
.
;
-
».
,
-
1b (
,
),
–
(
1).
-III,
,
-
:«
,
H.pylori
.
20
100 000
(
2006 .
000,
30,5,
).
37,2/100
–
World Standard – 20,5 (
– 14, 2).
H.pylori
»,
-
2b (
,
,
.
-
,
.
,
–B(
2).
,
,
-
)
2008 .
(2006 .),
,
[7].
.
-
-
,
.
.
-
,
-
,
.
-
.
-
-
.
(1)
9 4
(A):
H.pylori
;
2
.
,
,
1 2009
17
,
.
.
,
,
,
,
.
.
-
,
,
–
.
,
-
.
,
»,
,
.
.
1991 .
-
,
(
,
)
.
,
.
-
?
.
H.pylori
1-
-
,
-
.
,
,
.
.
-
.
-
,
-
,
.
.
,
,
-
.
,
,
».
,
.
-
.
:«
,
-
…».
–
.
-
-
.
,
,
-
.
95
.
,
:
.
H.pylori
,
-
,
.
-
.
.
.
,
-
,
,
Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 167180.
2. Curr ent concepts in the management of
Helicobacter pylori infection – The Maastricht III
Consensus Report / P. Malfertheiner [et al.] // Gut. –
2007. – Vol. 56. – P. 772-781.
3. Gisbert, J. P. Systematic review and meta-analysis:
levofloxacin-based rescue regimens after
Helicobacter pylori treatment failure / J. P. Gisbert,
F. De La Morena // Aliment. Pharmacol. Ther. – 2006.
– Vol. 23. – P. 35-44.
4.
, . .
Helicobacter pylori:
,
/ . .
, . .
, . .
//
.
.
,
,
. – 2007. – . 17,
1. – . 48-55.
5. Alteration of histological gastritis after cure of
Helicobacter pylori Infection / M. Hojo [et al.] //
Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P.
1923-1932.
6. Helicobacter pylori eradication improves gastric
histology and decreases serum gastrin, pepsinogen I
and pepsinogen II levels in patients with duodenal ulcer
/ S. Pimanov [et al.] // J. Gastroenterol. Hepatol. –
2008. – Vol. 23. – P. 1666-1671.
7. Asia Pacific consensus guideline on gastric cancer
prevention / K. M. Fock [et al.] // J. Gastroenterol.
Hepatol. – 2008. – Vol. 23. – P. 351-365.
210023,
.
.
,
,
.
, 27.
,
2
1. Current concepts in the management of
Helicobacter pylori infection – The Maastricht 22000 Consensus Report / P. Malfertheiner [et al.] //
: 8 (0212) 21-22-92,
e-mail: Pimanov-S@tut.by
.
8.01.2009 .
9 6
,